Trial Profile

Exploratory clinical study to examine safety and efficacy of iPS cell-derived corneal endothelial cell substitutes for bullous keratopathy (CLS001)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 14 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CLS 001 Cellusion (Primary)
Indications Corneal disorders
Focus Adverse reactions; First in man

Most Recent Events

27 Mar 2023 Results presented in a Cellusion media release.
27 Mar 2023 According to a Cellusion media release, Dr. Shigeto Shimmura and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference that the iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient.
12 Jan 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com